NATR

Business Context and Reporting Period

Company: Nature's Sunshine Products, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2003
Business Overview: The Company manufactures and distributes health and wellness products through a direct sales network of independent distributors and managers. Operations are segmented geographically into the United States, Latin America, Asia Pacific, and Other international markets.

Key Financial Metrics

(Amounts in thousands, except per share data)

Margins (Six Months 2003):
- Gross Margin (Sales less COGS): ~82.2%
- Operating Margin: 3.4%
- Net Profit Margin: 1.9%

Material Changes vs. Prior Period

• Revenue Decline: Sales revenue decreased 6.0% for the quarter and 5.5% for the six months compared to the prior year. This was driven primarily by a 12.9% decline in international sales.
• Segment Performance:
  • United States: Sales were relatively flat (down 1.6% QoQ, flat YoY for six months) due to lower volumes offset by a price increase in April 2003.
  • Latin America: Sales dropped 16.7% (six months) due to the devaluation of the Venezuelan Bolivar and Brazilian Real, alongside import restrictions.
  • Asia Pacific: Sales fell 34.0% (six months) primarily due to increased competition in South Korea.
  • Other Markets: Sales increased 29.8% (six months), driven by growth in the Russian Federation and United Kingdom.
• Profitability: Net income for the quarter dropped 62.7% year-over-year to $1.1 million, largely due to a $1.8 million impairment charge on an investment in HealtheTech Corporation. However, net income for the six-month period increased 28.1% to $2.7 million compared to the prior year.
• Expense Management: Selling, general, and administrative (SG&A) expenses decreased 5.7% for the six months due to cost control measures implemented in late 2002.
• Tax Rate: The effective income tax rate decreased significantly to 32.0% for the six months (from 55.8% in the prior year) due to the utilization of foreign subsidiary losses.

Guidance, Outlook, and Risks

• Outlook: Management expects cost of goods sold to decrease slightly as a percentage of sales for the remainder of 2003 due to the April price increase and potential currency stabilization. SG&A expenses are expected to decrease slightly as a percentage of sales. The annual effective tax rate is projected to be approximately 32%.
• Capital Allocation: The Company repurchased 1,326 shares of common stock for $11.8 million during the first six months of 2003. A new 1,000-share buyback program was authorized in March 2003 and fully executed by June 30, 2003.
• Liquidity: The Company maintains a $15 million unsecured line of credit, with $10 million outstanding as of June 30, 2003. Management believes working capital needs can be met through cash, operations, and the credit line.
• Risks and Contingencies:
  • Foreign Operations: Continued economic and political instability in Venezuela and currency devaluations in Latin America pose significant risks. Competition in South Korea remains a challenge.
  • Product Liability: The Company faces inherent risks regarding ingested products. Due to regulatory scrutiny on ephedrine alkaloids and kava, the Company could not obtain standard insurance for these products and established a captive insurance company in June 2003. There is no assurance that accrued liabilities are sufficient.
  • SEC Review: The SEC accounting staff reviewed the 2002 Form 10-K and requested clarification on several accounting issues. The Company is in the process of providing additional information.

Investor Verification Checklist

• Investment Impairment: Verify the nature and recoverability of the $1.8 million impairment charge related to the HealtheTech Corporation investment.
• Foreign Currency Exposure: Assess the ongoing impact of the Venezuelan Bolivar and Brazilian Real devaluations on future revenue and asset valuations in Latin America.
• Product Liability Reserves: Review the actuarial assumptions used for the new captive insurance company and the adequacy of reserves for ephedrine/kava-related claims.
• SEC Correspondence: Monitor the status of the SEC's review of the 2002 10-K and any potential restatements or adjustments resulting from the staff's inquiries.
• Debt Covenants: Confirm continued compliance with the financial covenants of the $15 million line of credit, especially given the volatility in international operations.